Search

Search Constraints

You searched for: Author/Creator Currier, Judith

Search Results

1. 1609Plasma markers of immune activation likely reflect related but distinct processes of cellular immune activation in HIV-infected persons before and after suppression of viremia by antiretroviral therapy: ACTG 5260. (December 2014)

2. Adipokines, Weight Gain and Metabolic and Inflammatory Markers After Antiretroviral Therapy Initiation: AIDS Clinical Trials Group (ACTG) A5260s. (12th June 2021)

3. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. (16th June 2021)

4. Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s. (29th August 2016)

5. Changes in the Fungal Marker β-D-Glucan After Antiretroviral Therapy and Association With Adiposity. (11th November 2019)

6. Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV). (17th August 2022)

7. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Issue 10281 (3rd April 2021)

9. LB2. Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients. (4th December 2021)

10. Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy. (10th May 2022)